6th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress UK

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	08:55 - 09:00
NEW ANTIBODY FORMATS & CELLULAR THERAPY
CAR T cells: From bench to bedside, looking toward the future of CAR T treatment Anat Globerson Levin, Director Immunology Lab, R&D, Tel-Aviv Sourasky Medical Center	09:00 - 09:25
The B cell and antibody response in patients with solid tumours Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	09:25 - 09:50
CDx strategies to support successful development of Immunotherapies Patricia McLoughlin, Senior Director Business Development, Oncology & Precision Diagnostics, Qiagen	09:50 - 10:20
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:20 - 10:50
From the bench to the market: Thermo Fisher Scientific enables your journey from RnD, to launching a commercial product James Watson , Senior Business Development Manager, Thermo Fischer Scientific, UK	10:50 - 11:20
Development of Next-Generation Antibody Fragment Drug Conjugates Tailored for Gastric Cancer Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	11:20 - 11:45
Neo-X-Prime™ bispecific antibodies targeting CD40 and tumor antigens Anette Sundstedt, Principal Scientist, Alligator Bioscience	11:45 - 12:10
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Jessica McDonough, Co-Founder, Attivare Therapeutics	12:35 - 13:05
Anti-glycan mabs are good carriers of drug conjugates Mireille Vankemmelbeke, Principle Scientist, Scancell	12:40 - 13:05
Lunch and Poster Presentations \| One-to-One Networking Meetings \| Chaired by Kenji Hashimoto, Chief Medical Officer, Crescendo Biologics	13:05 - 14:05
Non-Viral Transfection for Cell Therapy Applications Valeria Annibaldi, Group Leader, R&D Transfection, Lonza	14:05 - 14:20
CAR T-cell immunotherapy of solid tumours: Parallel learning from the clinic and lab John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio	14:20 - 14:45
Exploiting gamma delta TCR targeting to enable safe and effective cell therapies for solid tumors Mark Throsby, Chief Scientific Officer, Gadeta BV	14:45 - 15:10
T-cell homing in cancer immunotherapy Ann Ager, Professor, Cellular Immunity and Immunotherapy, Cardiff University	15:10 - 15:35
Afternoon Refreshments and Poster Presentations \| One-to-One Networking Meetings	15:35 - 16:05
Update in development of bispecific Abs Kenji Hashimoto, Chief Medical Officer, Crescendo Biologics	16:05 - 16:30
From One Week to One Day: Take Control of Your Research by Automating Tissue Microarrays, Multiplexing, Whole Slide Scanning and AI Analysis for Enhanced Bioinformatics Hannaneh Davatgar, Senior Product Specialist and, Matthew Cashmore, Senior Product Specialist, Epredia	16:30 - 17:00
Adenosine and TIM3 directly suppress cytolytic killing of tumour target cells via inhibition of cytoskeletal polarisation Christoph Wuelfing, Professor, Immunology, University of Bristol	17:00 - 17:25
Generation of allogeneic CAR T-cell therapies based on a novel γδ T-cell platform Marc Davies, VP, CAR Engineering, Leucid Bio	17:25 - 17:50
Systemic immune reaction in lymph nodes adds prognostic information for breast cancer patients Anita Grigoriadis, Reader in Cancer Bioinformatics, King’s College London	17:50 - 18:15
Closing remarks from the Chairman \| End of Day 1 followed by Drinks Reception and Networking Kenji Hashimoto, Chief Medical Officer, Crescendo Biologics	18:15 - 18:30
End of Day 1 followed by Drinks Reception and Networking	18:30 - 18:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
NEW IMMUNE CHECKPOINTS, BIOMARKER AND TUMOUR MICROENVIRONMENT
Keynote: New widely-expressed cancer targets by dissection of successful cancer immunotherapy Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University	09:00 - 09:25
Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices	09:25 - 09:55
Invasive cancers generate immunosuppressive microenvironments Victoria Sanz-Moreno , Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK	09:55 - 10:20
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:20 - 10:50
Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc	10:50 - 11:20
Therapeutic targeting of a novel family of myeloid checkpoint inhibitors Ali Roghanian, Assistant Professor, Cancer Immunology, University of Southampton, UK	11:20 - 11:45
The metastatic niche – De-construct the different cellular components within a tumour to identify new therapeutic targets Luigi Ombrato, Group Leader, Barts Cancer Institute	11:45 - 12:10
Engineering strategies for improving adoptive T-cell therapy of cancer Melita Irving, Group Leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Ludwig Institute for Cancer Research	12:10 - 12:35
Potential of vaccines for refractory patients John Maudsley, CEO, Cancer Vaccines Ltd	12:35 - 13:00
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:00 - 14:00
Using Metabolimics to Synchronize and optimize Immune-Oncology Strategies Brian Keppler , Director, Discovery and Translational Sciences, Metabolon	14:00 - 14:30
How Biomarker multi-omics approach from Veracyte brings value to Biopharma drug development programs? Corinne Danan, General Manager, Biopharma, Veracyte	14:30 - 15:00
Adressing Tumor Heterogeneity with Oncolytic Molecules - an unsolved issue in Cancer Immunotherapy OR, CEO, Lytix Biopharma	15:00 - 15:25
Small activating RNA from concept to Phase 2 clinical trials Nagy Habib, Founder and Head of R&D, MiNA Therapeutics	15:25 - 15:50
End of Conference	16:00 - 16:00
Closing remarks from the Chairman \| End of Conference	16:15 - 16:15